Business
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers
About this update from Lakewood-amedex Biotherapeutics Inc.
[{"type":"text","content":"Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patentsSARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the \"Company\"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance of two patents, one each in Australia and New Zealand respectively.\n \n \n \n \n \n \n \nThe two patents are directed to the gel formulation of the Bisphosphocin® Nu-3, which is being advanced into a Phase 2 clinical trial for the treatment of mildly infected diabetic foot ulcers (iDFU). The gel formulation of the topically applied Nu-3 is designed specifically to adhere to wounds and comprises lyotropic liquid crystals that form a mobile network through hydrogen bonding to water.\"These newly issued patents further strengthen and expand our global intellectual property portfolio surrounding the Bisphosphocin platform, which we believe is one of our company's most important strategic assets,\" said Kelvin Cooper, Chief Executive Officer of Lakewood-Amedex Biotherapeutics. \"As we advance the development of Nu-3 and our broader pipeline of novel antimicrobial compounds, expanding our worldwide patent estate remains central to protecting our innovation, enhancing future commercial opportunities, and creating long-term shareholder value. With almost 100 granted and pending patents, we believe Lakewood-Amedex Biotherapeutics is building a strong competitive position in the fight against antimicrobial resistance.\"New patents directed to Bisphosphocin gel formulations:On February 3, 2026, The Intellectual Property Office of New Zealand (IPONZ) granted patent number 759577, titled, \"Bisphosphocin Gel Formulations and Uses Thereof.\"On March 19, 2026, IP Australia granted Patent Number 2024202211, titled, \"Bisphosphocin Gel Formulations and Uses Thereof.\"These two new patents expand the number of granted patents for the Nu-3 gel formulation to 27 patents, covering the following geographical regions - United States, European Patent Office (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy,...